Close

iBio, Inc. (IBIO) Notified by EPO of Patent Expiration; No Challenge Filed

November 30, 2015 8:32 AM EST

iBio, Inc. (NYSE: IBIO) announced it has received notice from the European Patent Office that the opposition period for a patent granted to iBio has expired and no opposition has been filed.

"This patent strengthens protection of our innovative plant-made protein production technology," stated Robert Erwin, iBio's President. "In combination with our expanded use of Novici Biotech's patented GRAMMR gene and protein enhancement technology, we are addressing opportunities to increase the expression yield of therapeutic proteins such as antibodies, improve their functional properties, and reduce production costs versus conventional approaches.

The patent, entitled "Systems and Methods for Clonal Expression in Plants" (European patent EP 1769068), includes claims to a system for generating transgenic hairy root cells containing a viral vector expressing a gene of interest. The system is used to generate a clonal root line, clonal root cell line, clonal plant cell line, or clonal plant having a self-replicating, episomal, extrachromosomal viral RNA vector that carries a polynucleotide of interest.

"The protein expression technologies covered by this patent have particular utility for companies interested in producing proteins in plant cell culture," said Wayne P. Fitzmaurice, Ph.D., iBio's Vice President of Intellectual Property. "Current strategies for expression of proteins in plants typically use whole plants grown in controlled environmental chambers or plant cell culture in a bioreactor. iBio has multiple proprietary systems enabling us and our clients to select the most efficient technology for a specific biopharmaceutical depending on its characteristics and commercial applications."

New Chinese Patent Granted to iBio

In addition iBio has received a notice of grant for a Chinese patent in the company's iBioModulator" thermostable immunomodulator protein portfolio, a group of patents important to the company's vaccine technology business. The patent, serial number CN103074316, is entitled "Recombinant Carrier Molecule for Expression, Delivery, and Purification of Target Polypeptides." The composition of matter and methods claims grant iBio important additional exclusivity over new, modified carrier molecules derived from the company's proprietary iBioModulator" thermostable immunomodulator protein system and their use with target proteins or antigens.

"Expanding our intellectual property portfolio in European countries and China is an important part of our overall strategy to create and optimize more efficient technologies to meet the growing demand for affordable, high quality biologic products," noted Robert Erwin, iBio's President.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Life Enjoyed, Management Comments